Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 6

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 6
---
83</div>

We are a “foreign private issuer,” as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are exempt from certain rules under the Exchange Act that impose certain disclosure obligations and procedural requirements for proxy solicitations under Section 14 of the Exchange Act. In addition, our officers, directors and principal shareholders are exempt from the reporting and “short-swing” profit recovery provisions under Section 16 of the Exchange Act. Moreover, we are not required to file periodic reports and financial statements with the Securities and Exchange Commission as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.

As a foreign private issuer, we have elected to follow home country practice instead of complying with NASDAQ Listing Rule 5635(d) shareholder approval requirements, we are not required to obtain, and do not intend to seek, shareholder approval of the issuance of the Units, to the extent that such approval would otherwise be required for a domestic issuer.

Investing in our securities involves risks. See “Risk Factors” beginning on page [•] of this prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities.

<div align='center'>___________________</div>

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

|                                          |     |   | Per Unit(1) |     |   | Per Pre-Funded Unit(2) |     |   | Total |
|:-----------------------------------------|:----|:--|:------------|:----|:--|:-----------------------|:----|:--|:------|
| Public offering price                    |     | $ |             |     | $ |                        |     | $ |       |
| Underwriter discounts and commissions(3) |     | $ |             |     | $ |                        |     | $ |       |
| Proceeds, before expenses, to us         |     | $ |             |     | $ |                        |     | $ |       |

________

| (1) | The public offering price and underwriting discount in respect of such Unit corresponds to (i) a 
 public offering price per Depositary Share of $       ($       net of the                        
 underwriting discount), and (ii) a public offering price per Series L Warrant of $      .        |

| (2) | The public